MA42743A1 - Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f - Google Patents

Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Info

Publication number
MA42743A1
MA42743A1 MA42743A MA42743A MA42743A1 MA 42743 A1 MA42743 A1 MA 42743A1 MA 42743 A MA42743 A MA 42743A MA 42743 A MA42743 A MA 42743A MA 42743 A1 MA42743 A1 MA 42743A1
Authority
MA
Morocco
Prior art keywords
antibody molecules
tnf
alpha
specificity
multispecific antibody
Prior art date
Application number
MA42743A
Other languages
English (en)
Inventor
Stevan Graham Shaw
Diane Marshall
Sam Philip Heywood
Ralph Adams
Pallavi Bhatta
Emma Dave
David Paul Humphreys
Daniel Lightwood
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA42743A1 publication Critical patent/MA42743A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'anticorps multispécifiques pour tnf alpha, il-17a et il-17f, des utilisations thérapeutiques de ces molécules d'anticorps et des procédés pour la production desdites molécules d'anticorps.
MA42743A 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f MA42743A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522391.0A GB201522391D0 (en) 2015-12-18 2015-12-18 Antibody molecules
PCT/EP2016/080979 WO2017102830A1 (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Publications (1)

Publication Number Publication Date
MA42743A1 true MA42743A1 (fr) 2019-07-31

Family

ID=55311227

Family Applications (2)

Application Number Title Priority Date Filing Date
MA044061A MA44061A (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
MA42743A MA42743A1 (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA044061A MA44061A (fr) 2015-12-18 2016-12-14 Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f

Country Status (25)

Country Link
US (1) US20200277366A1 (fr)
EP (1) EP3390445A1 (fr)
JP (1) JP2019502380A (fr)
KR (1) KR20180089514A (fr)
CN (1) CN108473568A (fr)
AR (1) AR107735A1 (fr)
AU (1) AU2016369307A1 (fr)
BR (1) BR112018011860A2 (fr)
CA (1) CA3007493A1 (fr)
CL (1) CL2018001660A1 (fr)
CO (1) CO2018006667A2 (fr)
EA (1) EA201891446A1 (fr)
EC (1) ECSP18054047A (fr)
GB (1) GB201522391D0 (fr)
IL (1) IL259645A (fr)
MA (2) MA44061A (fr)
MX (1) MX2018007289A (fr)
PH (1) PH12018501141A1 (fr)
RU (1) RU2018126318A (fr)
SG (1) SG11201804803WA (fr)
TN (1) TN2018000200A1 (fr)
TW (1) TW201726731A (fr)
UY (1) UY37035A (fr)
WO (1) WO2017102830A1 (fr)
ZA (1) ZA201803681B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005031A (es) 2015-10-27 2018-06-13 Ucb Biopharma Sprl Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2022223152A1 (en) * 2021-02-19 2023-08-31 Innovent Biologics (Suzhou) Co., Ltd. Anti-gprc5d×bcma×cd3 trispecific antibody and use thereof
CN117642423A (zh) * 2021-09-13 2024-03-01 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
KR20170023209A (ko) * 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
UA117218C2 (uk) * 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
UY34410A (es) * 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2015014979A1 (fr) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Anticorps bispécifiques anti-tnfa-il-17

Also Published As

Publication number Publication date
MX2018007289A (es) 2018-09-28
CN108473568A (zh) 2018-08-31
KR20180089514A (ko) 2018-08-08
EP3390445A1 (fr) 2018-10-24
WO2017102830A1 (fr) 2017-06-22
RU2018126318A (ru) 2020-01-20
ZA201803681B (en) 2019-09-25
AR107735A1 (es) 2018-05-30
ECSP18054047A (es) 2018-07-31
CO2018006667A2 (es) 2018-07-10
AU2016369307A1 (en) 2018-07-12
UY37035A (es) 2017-07-31
TW201726731A (zh) 2017-08-01
CA3007493A1 (fr) 2017-06-22
TN2018000200A1 (en) 2019-10-04
MA44061A (fr) 2018-10-24
CL2018001660A1 (es) 2018-10-19
BR112018011860A2 (pt) 2018-12-04
IL259645A (en) 2018-07-31
RU2018126318A3 (fr) 2020-05-20
JP2019502380A (ja) 2019-01-31
SG11201804803WA (en) 2018-07-30
EA201891446A1 (ru) 2018-11-30
GB201522391D0 (en) 2016-02-03
PH12018501141A1 (en) 2019-01-28
US20200277366A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
MA42743A1 (fr) Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2019011916A (es) Anticuerpos anti-lag3.
EA202092435A2 (ru) Моноклональные антитела против bcma
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MA34907B1 (fr) Molécules d'anticorps se liant à il-17a et il-17f
MA35724B1 (fr) Molécules d'anticorps ayant une spécificité pour des déterminants antigéniques de ox40 humain, des utilisations thérapeutiques de ces molécules d'anticorps et leurs procédés de production.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
MX2016016886A (es) Anticuerpos anti-axl.
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
PH12016500525A1 (en) Substituted phenylalanine derivatives
PH12020551791A1 (en) Methods for the production of methacrylates
EA201691677A1 (ru) Генетические локусы, связанные с повышенной фертильностью у маиса
EA201890177A1 (ru) Мультиспецифические связывающие белки
MA38475B1 (fr) Protéines spécifiques de baff et b7rp1 et leurs utilisations
MX2018007221A (es) Moleculas de anticuerpos que se unen al factor de necrosis tumoral alfa (tnf alfa).
EA201792578A1 (ru) Многослойная сборка
EA201991474A1 (ru) Способы получения фитоина
ZA202201221B (en) Cyclopentane compounds
EA201991471A1 (ru) Способы введения гепсидина